Verelan PM Articles
Eisai's Vasolan gets expanded Japanese indication
10 March 2008
Promising PKC data on AGI's IBS-D drug
25 February 2008
FDA accepts IND filing for AGI's arverapamil
24 September 2007
Headlines 25 years ago this week....
29 January 2007
Schwarz's 1st-qtr sales up 4% to 274M euros
8 May 2006
Schwartz Pharma boosted by US sales
9 May 2005
Danger from same brand names for different drugs
7 February 2005
Wide changes in US generics' prices: study
15 November 2004
Abbott buys rights to Aventis' tranolapril
14 June 2004
Janssen-Cilag's topiramate expected to grow migraine prevention market
29 September 2003
France to reimburse drugs at generics prices
30 June 2003
Schwarz forecasts two-fold earnings growth in 2003
3 March 2003
Brand name confusion "a risk for patients"
27 May 2002
Elan plans $40 mill expansion at Gainesville, USA
1 April 2002
Schwarz Pharma looks to have turned corner
12 November 2001
Schwarz Pharma net income up 65% as operating loss narrows
21 February 2001
BASF sells pharma business to Abbott Labs for $6.9 billion in cash
15 December 2000
Duramed and Solvay expand marketing pact
7 March 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Kos Pharmaceuticals gets $50 million boost
20 December 1999
Hefty increase in 3rd qtr revenues at Elan
26 October 1999
Schwarz posts sharp first-half profits rise
6 August 1999
Kos to co-promote Knoll's antihypertensives
29 July 1999
Schwarz/Elan launch Verelan PM
29 March 1999
4th qtr revenues rise 96% at Elan
12 February 1999
Elan Completes Ziconotide Phase III In Neuropathic Pain
15 December 1998
FDA Approves Elan's Verelan PM
2 December 1998
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
Elan Grants US Verelan Rights To Schwarz
13 October 1998
Chiroscience Stock Yo-Yos After Gene Discovery
7 October 1998
Fast Growth Seen For BASF's Pharma Unit
7 October 1998
Elan Regains Naprelan And Verelan Rights
24 September 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
Merged AHP/Monsanto Will Be Top US Drugmaker
15 June 1998
BASF Makes Strong Start To 1998, Sales Up 7.4%
21 May 1998
Elan Posts Record Growth In 1st Quarter 1998
27 April 1998
BASF Not Looking To Sell Pharma Business
30 March 1998
Strong Growth At Elan Corp, Net Income Up 51%
9 February 1998
Teva Enters Marketing Deal With Biovail
18 December 1997
Knoll Launches Tarka Combination In UK
11 November 1997
Elan Acquires Hypertensives
30 October 1997
Net Income And EPS Soar At Ireland's Elan Corp
22 October 1997
New Indication For Knoll's Securon In UK
4 September 1997
Chiroscience To Put Cancer Drugs In Clinic In 4Q97
17 March 1997
Russian Drug Output Fails To Meet Demand
27 January 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
Chiroscience Hopes Verapamil Isomer Could Cut Constipation
20 January 1997
BASF/Knoll Considering More Investment In India
20 January 1997
Biovail Shares Soar On Firm's Good News
9 December 1996
Patent Dispute Settled Between Biovail And Elan
2 December 1996
Knoll's Tarka Receives FDA Approval
18 November 1996
Frenetic 12 Months For SkyePharma
14 October 1996
Ivax Unveils $13 Million Restructuring Program
7 October 1996
Boots Buy Boosts BASF In 1996 First Half
2 September 1996
Chiroscience Gets First Product Approval
8 July 1996
First Chronotherapeutic In Cardiology; Covera-HS
17 June 1996
Earnings Growth In Excess of 25% At Elan?
15 April 1996
BASF To Introduce 4 New Drugs In 1996-7
8 April 1996
Mylan's Generic Isoptin SR
1 April 1996
Delivering Drugs At The Right Time: Chronobiology
25 March 1996
Searle's "Biorhythm" Drug Gets US Approval
25 March 1996
Recordati Expects Imminent Approval Of Zanidip In UK
25 March 1996
BASF-Knoll Seeks Pharma Research Partner
4 March 1996
UK Industry Code of Practice: latest Report
4 March 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
Searle's Covera-HS Nears US Market
5 February 1996
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
Interim Sales Soar At Chiroscience
9 October 1995
JAMA Study Ups Debate Over Calcium Blockers
4 September 1995
Generics: A Passage Through Time
4 September 1995
Benefits Of Drug Delivery Systems For Generics
5 June 1995
Boots Deal Strengthens Pharma At BASF
17 April 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
Ivax-Zenith: World's Largest Generics Firm
10 April 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
BASF Optimistic On Future With Good 1995 Start
3 April 1995
Knoll And Ivax Set Up Euro Generics JV
27 March 1995
Calcium Channel Blockers Raise Heart Attack Risk?
20 March 1995
Chiroscience Details Research Programs
6 February 1995
Ivax Completes Zenith Appointment
16 January 1995
Sidmark To Distribute For Searle
2 January 1995
MDR: Misunderstood Drug Resistance?
5 December 1994
Zenith Ends Agreement With G D Searle
5 December 1994
Trandolapril Shows Significant Benefit In Post-MI Patients
19 September 1994
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
IMPACT OF SWEDISH REFERENCE PRICING PLAN
6 June 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
COOPER DELAYS VERAPAPMIL FILING
9 May 1994
GENERIC DRUGS AND DELIVERY SYSTEMS
18 April 1994
IVAX SUFFERS OVER GENERIC THREAT
11 April 1994
IVAX BEGINS MARKETING OF NEW VERAPAMIL FORMULATION
11 April 1994
ZENITH TO MARKET VERAPAMIL
28 March 1994
N AMERICAN PHARMA MARKET STUDIED
28 February 1994
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
